Skip to main content

gotistobart

Generic: Gotistobart

gotistobart: 2 clinical trials tracked.

gotistobart evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about gotistobart, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Non-Small Cell Lung Cancer
Clinical Trials (2)

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510·Phase 3
Active, not recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen630 targetStarted 2023-06Completion 2028-0850 sites · Australia, United StatesOncoC4, Inc.

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189·Phase 1·BNTX
Recruiting

Primary endpoint: Cohorts 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, EGFR and ALK/RET: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period

Interventionalopen320 targetStarted 2022-06Completion 2031-1145 sites · Australia, Germany, Hungary, Poland…BioNTech SE